Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating
several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with …

Background No targeted drugs are currently available against small cell lung cancer
(SCLC). BCL-2 family members are involved in apoptosis regulation and represent …

Small-cell lung cancer (SCLC) is generally considered a'homogenous' disease, with little
documented inter-tumor heterogeneity in treatment guidance or prognosis evaluation. The …

Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in
lung cancer management, providing first-time improvements in patient response, prognosis …

Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is
broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer …

Objective Despite major progress over the past decade in the field of lung cancer care, only
mild advances have occurred in Small Cell Lung Cancer (SCLC), with prognosis remaining …

Small cell lung cancer (SCLC) is a particular subtype of lung cancer with high mortality.
Recent advances in understanding SCLC genomics and breakthroughs of immunotherapy …

Second-line treatment options for patients with relapsed, extensive-stage small cell lung
cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis …